Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 4Q Financial Reports: Amgen | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

4Q Financial Reports: Amgen

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Amgen

4Q Revenues: $3.3 billion (+12%)

4Q Earnings: $928 million (+24%)

FY Revenues: $12.4 billion (+18%)

FY Earnings: $4 billion (+28%)

Comments: Worldwide sales of Aranesp increased 24% to $873 million in the quarter and sales for the year were $3.3 billion, up 32%. Sales of Neulasta and Neupogen were $928 million in the quarter, an increase of 19% and sales were $3.5 billion for the year, up 20%. Enbrel sales were up 19% for the quarter to $674 million and sales increased 35% to $2.6 billion for the year. R&D expenses totaled $658 million during the quarter, up 8% and $2.3 billion for the year, up 15%. Staff-related expenses and key clinical trials, including the large-scale Phase III trials for denosumab, an investigational therapy for bone loss, drove 4Q and FYincreases.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics